ClinicalTrialsFinder
RecruitingPhase 2NCT05725200

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal Cancer

Sponsor

Oslo University Hospital

Enrollment

40 participants

Start Date

Sep 27, 2022

Study Type

INTERVENTIONAL

Conditions

Metastatic Colorectal Cancer

Summary

The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer). All patients included must have metastatic bowel cancer and receive or have received at least two lines of standard chemotherapy. The cancer must not be available for surgery with curative intent.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether tailoring treatment based on individual tumor biology can improve outcomes for people with advanced colorectal cancer that has spread and cannot be removed by surgery. Researchers will analyze tumor samples to guide which treatments are used. **You may be eligible if...** - You have been diagnosed with advanced (metastatic) colon or rectal cancer confirmed by biopsy - Your cancer has spread and cannot be surgically removed - You are currently receiving or have received systemic treatment for metastatic colorectal cancer - You are in reasonably good health (ECOG 0 or 1) **You may NOT be eligible if...** - You have a serious medical condition that would interfere with the study - Your tumor cannot be safely biopsied - You are unable to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAlectinib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current Summary of Product Characteristics (SMPC) and package Insert.

DRUGCetuximab

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUGCrizotinib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUGDasatinib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUGEverolimus

Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.

DRUGEncorafenib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUGGemcitabine

Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.

DRUGIdelalisib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUGLarotrectinib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUGMethotrexate

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUGPalbociclib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUGPanobinostat

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUGPembrolizumab

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUGPetrozumab

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUGTrastuzumab

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUGTalazoparib

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

DRUGVenetoclax

Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.

Locations(1)

Oslo University Hospital

Oslo, Norway

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05725200

Related Trials

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

NCT061494811 location

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

NCT011741211 location

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT0492922376 locations

New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

NCT075597601 location

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649286 locations